Human CD8 T cell targeted LNP kit (SV106Delivery)

The ready-to-use LNP kit enables specific delivery to human CD8 T cells. It is intended for research use only, supporting proof-of-concept studies and screening of mRNA constructs human PBMCs.

Kit Components

SV106-36 Delivery for Human CD8 T Cells delivery of 36 μg mRNA. The kit contains 3 x 300μL Lipid Mixture, 1 x 1.5mL Formulation Buffer, 1 x 3mg Reagent A, 1 x 400 μL Reagent B-6. For Research Use Only

SV106-120 Delivery Plus for Human CD8 T Cells delivery of 120 μg mRNA. The kit contains 5 x 600μL Lipid Mixture, 2 x 2mL Formulation Buffer, 2 x 3mg Reagent A, 2 x 600μL Reagent B-6. For Research Use Only

Cell-type specificity: Enabling targeted delivery to human CD8 T cells with exceptional selectivity.

Human CD8 T cell targeted SV106Delivery^™ Kits information andSupporting Data

Table 4 The Characterizations of human CD8 T cell targeted LNP-mRNA generated by SV106Delivery^™ Kits

The kits exhibit excellent encapsulation efficiency, generate nanoparticles with a uniform average size of approximately 100 nm, and maintain a low polydispersity index (PDI).

Figure 7. Stability of human CD8 T cell targeted LNP-mRNA generated by SV106Delivery^™ Kits. The human CD8 T cell targeted LNP-mRNA underwent three freeze–thaw cycles prior to transfect mouse splenic cells. Shown are nanoparticle size (A), polydispersity index (PDI) (B), and transfection efficiency in human PBMC cells (C).

Figure 8. The SV106Delivery^™ kit demonstrated robust transfection efficiency and cell-type specificity in human PBMC cells. In vitro transfection efficacy: Human PBMC cells were transfected with LNP–mRNA encoding eGFP, formulated using the SV106Delivery^™ kit as indicated. Shown are representative FACS plots (A) and the percentage of GFP⁺ cells (B) one day post-transfection, as determined by flow cytometry.

Store Temperature

Formulation Mixture: -80°C

Formulation Buffer: Room Temperature

Reagent A: Room Temperature

Reagent B-6: 4°C